After underperforming the overall market for the past few years, large-cap pharmaceutical stocks may now be positioned to ...

West Pharmaceutical Services, Inc.'s Q2 results highlight growth driven by GLP-1 drugs and high-value products. Click for WST ...

In Q2 2025, West Pharmaceutical's revenues increased by 9.17%, suggesting that the destocking effect is vanishing. Read why ...

Eramol, a UK-based pharmaceutical contract development and manufacturing organisation (CDMO), is pleased to announce ...

Industry observers, concerned about FIS’s future, questioned whether the Ferrari family, its owner, could continue to run a company that had grown to over 2,000 employees and 300 customers.

Americans cannot absorb billions in added drug price hikes as a result of ill-designed and poorly timed tariff increases.

West Pharmaceutical Services (WST) came out with quarterly earnings of $1.84 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.52 per share a year ago ...

According to Journal Biostatistics, only 13%-14% of more than 20,000 drug candidates from all disease areas entering the development process from the year 2000 to 2015 will ultimately be approved ...

Setbacks For Pharmaceutical Industry In Challenges To Medicare Drug Price Negotiations Zachary Baron Sheela Ranganathan March 21, 2024 10.1377/forefront.20240319.517157 Sections ...